首页> 美国卫生研究院文献>BMJ Open Diabetes Research Care >Glucose-lowering effects and safety of DS-8500a a G protein-coupled receptor 119 agonist in Japanese patients with type 2 diabetes: results of a randomized double-blind placebo-controlled parallel-group multicenter phase II study

【2h】

Glucose-lowering effects and safety of DS-8500a a G protein-coupled receptor 119 agonist in Japanese patients with type 2 diabetes: results of a randomized double-blind placebo-controlled parallel-group multicenter phase II study

机译：DS-2500a（一种G蛋白偶联受体119激动剂）在日本2型糖尿病患者中的降糖作用和安全性：一项随机双盲安慰剂对照平行组多中心II期研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

ObjectiveDS-8500a is a novel G protein-coupled receptor 119 agonist being developed for the treatment of type 2 diabetes. The study objective was to assess the efficacy and safety of DS-8500a in Japanese patients with type 2 diabetes.

机译：ObjectiveDS-8500a是一种新型G蛋白偶联受体119激动剂，正在开发中，用于治疗2型糖尿病。研究目的是评估DS-8500a在日本2型糖尿病患者中的疗效和安全性。

著录项

期刊名称 BMJ Open Diabetes Research Care
作者
Nobuya Inagaki; Hubert S Chou; Shuji Tsukiyama; Takuo Washio; Kazuhito Shiosakai; Yasuhiko Nakatsuka; Takashi Taguchi;
展开▼
作者单位

展开▼
年(卷),期 2017(5),1
年度 2017
页码 e000424
总页数 9
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
G protein-coupled receptor 119 agonist glycemic control Japanese phase II clinical trial type 2 diabetes;

机译：G蛋白偶联受体119激动剂;血糖控制;日本;II期临床试验;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study [J] . Nobuya Inagaki, Shuji Tsukiyama, Takashi Taguchi, BMJ Open Diabetes Research & Care . 2017,第1期

机译：DS-2500a（一种G蛋白偶联受体119激动剂）在日本2型糖尿病患者中的降糖作用和安全性：一项随机，双盲，安慰剂对照，平行组，多中心，II期研究的结果
2. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study [J] . Yuichiro Yamada, Yasuo Terauchi, Hirotaka Watada, Advances in therapy. . 2018,第3期

机译：GPR119 Agonist DS-8500A在2型糖尿病患者中的疗效和安全性：随机，双盲，安慰剂控制，12周的研究
3. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial [J] . Kaku K., Enya K., Nakaya R., Diabetes, obesity & metabolism . 2015,第7期

机译：在饮食和运动控制不充分的日本2型糖尿病患者中，G蛋白偶联受体40激动剂Fasiglifam（TAK-875）的疗效和安全性：一项随机，双盲，安慰剂对照的III期临床试验
4. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
5. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized Double-Blind Placebo-Controlled 12-Week Study [O] . Yuichiro Yamada, Yasuo Terauchi, Hirotaka Watada, -1

机译：GPR119激动剂DS-8500a在日本2型糖尿病患者中的疗效和安全性：一项随机双盲安慰剂对照的12周研究
6. Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study [O] . Yasuo Terauchi, Yuichiro Yamada, Hirotaka Watada, 2018

机译：日本型2型糖尿病患者的G蛋白偶联受体119激动剂DS-8500A的疗效和安全性具有不足的血糖对SITAGLIPTIN的血糖控制：A相随机安慰剂对照研究

Glucose-lowering effects and safety of DS-8500a a G protein-coupled receptor 119 agonist in Japanese patients with type 2 diabetes: results of a randomized double-blind placebo-controlled parallel-group multicenter phase II study

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅